Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

Company Overview - Junshi Biosciences is a leading innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies [1][8] - The company has a diversified R&D pipeline with over 50 drug candidates across five therapeutic areas: cancer, autoimmune, metabolic, neurological, and infectious diseases [8] - Junshi Biosciences has received approvals for five products in China and international markets, including toripalimab, the first domestically produced anti-PD-1 monoclonal antibody in China [8] Product Development - The recombinant humanized anti-IL-17A monoclonal antibody, JS005, has shown positive results in a Phase 3 clinical study for treating moderate to severe plaque psoriasis [1][3] - The study met both co-primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful improvements compared to the placebo group [1][4] - JS005 is designed to block IL-17A, a cytokine involved in autoimmune diseases, thereby alleviating symptoms of conditions like psoriasis [6] Clinical Study Insights - The Phase 3 study was conducted at 60 clinical sites across China, led by Professor Jianzhong ZHANG from Peking University People's Hospital [3] - Results indicated that a higher proportion of participants achieved a sPGA score of 0 or 1 with JS005 compared to the placebo, along with good safety profiles [4][5] - The study results will be presented at future international academic conferences, highlighting the significance of JS005 in psoriasis treatment [4] Market Context - Psoriasis affects approximately 125 million people globally, with a prevalence of 2.0% to 3.0% worldwide and 0.47% in China [2] - Patients with moderate to severe psoriasis face increased risks of metabolic syndrome, cardiovascular disease, and mental health issues, underscoring the need for effective treatments [2] - The successful Phase 3 study of JS005 represents a significant milestone in addressing the treatment gap for patients suffering from this chronic condition [5]